Financial Performance - The company's total revenue for 2023 was approximately ¥1.21 billion, a decrease of 2.69% compared to ¥1.24 billion in 2022[30]. - Net profit attributable to shareholders was approximately ¥126.20 million, down 42.32% from ¥218.79 million in the previous year[30]. - The basic earnings per share decreased to ¥0.31, a decline of 42.59% from ¥0.54 in 2022[30]. - Operating cash flow net amount was approximately ¥151.14 million, down 53.21% from ¥323.04 million in 2022[30]. - Total assets at the end of 2023 were approximately ¥3.10 billion, an increase of 1.36% from ¥3.06 billion at the end of 2022[30]. - Net assets attributable to shareholders increased by 5.55% to approximately ¥2.40 billion from ¥2.27 billion in 2022[30]. - The company reported a significant decline in quarterly net profit, with a loss of approximately ¥12.58 million in Q4 2023[32]. - The company reported a non-operating income of CNY 12.09 million in 2023, down from CNY 23.03 million in 2022[36]. - The company received government subsidies amounting to CNY 7.9 million in 2023, compared to CNY 11.65 million in 2022[36]. - The company reported a total revenue of 8,327 million for the year, maintaining the same figure as the previous period[113]. Market Position and Competition - The company reported a significant reliance on its main products, with the sales revenue from the Kuaike cold medicine series accounting for a high percentage of total operating income and gross profit[6]. - The company is facing increasing competition in the domestic market due to rising health awareness and potential entry of foreign pharmaceutical companies[4]. - The OTC market for cold medicine is significant, with an estimated 1.043 billion people in China suffering from colds annually, indicating a strong demand for self-medication products[41]. - The health food market in China is projected to grow from CNY 211.3 billion in 2022 to CNY 286.7 billion by 2027, with a compound annual growth rate of 6.3%[42]. - The Chinese herbal medicine industry is expected to reach a market size of CNY 8 trillion by 2030, with an annual growth rate of 10.3% from 2016 to 2030[43]. Research and Development - The company has a diverse R&D pipeline, including integrated raw material drug formulations and calcium mineral series products, but faces risks related to drug development and approval processes[7]. - The company plans to expand its product line and enhance R&D capabilities in new composite pipeline technologies[30]. - The company is actively pursuing several R&D projects, including the consistency evaluation of diclofenac sodium sustained-release tablets, aimed at enhancing product competitiveness[66]. - The total R&D investment in 2023 was ¥50,011,112.66, representing 4.14% of operating revenue, an increase from 3.15% in 2022[70]. - The company is committed to research and development, although specific figures or projects were not disclosed in the report[116]. Quality Control and Compliance - The company has implemented strict quality control measures, exceeding national standards, but still faces risks related to product quality and potential economic losses[7]. - The company acknowledges the impact of national policies on the pharmaceutical industry, including price control measures that may affect profit margins[8]. - The company has no significant discrepancies between financial reports prepared under international and Chinese accounting standards[33][34]. - The company has implemented various internal control systems to enhance operational efficiency and risk management[151]. - The company has established a clear internal control system with defined roles and responsibilities to mitigate risks[152]. Strategic Initiatives - The company plans to distribute cash dividends of 1.10 RMB per 10 shares to all shareholders, based on a total of 401,743,872.00 RMB[9]. - The company has initiated significant investment projects, such as the Jinxi raw material drug project, which carries risks if not successfully completed[7]. - The company is focusing on market expansion strategies to improve overall performance in the upcoming fiscal year[30]. - The company aims to enhance brand loyalty and influence among future consumer groups through targeted marketing strategies[53]. - The company is committed to a marketing-driven approach to overcome current growth bottlenecks, utilizing a diverse product cluster strategy to balance commercial risks and expand market share[96]. Environmental Responsibility - The company adheres to various environmental protection laws and standards, ensuring compliance in its operations[162]. - The company has established a monitoring system for wastewater discharge, ensuring compliance with environmental regulations[170]. - The company has implemented a new strategy for wastewater treatment, focusing on reducing nitrogen and phosphorus pollution[170]. - The company has engaged third-party monitoring for pollutant emissions as part of its environmental compliance strategy[180]. - The company has committed to achieving carbon peak and carbon neutrality goals through structured environmental responsibility[181]. Governance and Management - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring compliance with legal standards[106]. - The company held its first temporary shareholders' meeting on December 22, 2023, electing the fifth board of directors, which consists of 11 members, including 4 independent directors[103]. - The company has maintained compliance with governance standards, ensuring effective internal control and decision-making processes throughout the reporting period[102]. - The company has a governance structure in place with a mix of executive and independent directors, ensuring diverse oversight[113]. - The company has established a commitment to ensure that its shareholders, directors, supervisors, and senior management do not operate or assist in any competing business during their tenure[200].

四川金石亚洲医药股份有限公司 审计报告及财务报表 二○二三年度 四川金石亚洲医药股份有限公司 审计报告及财务报表 （2023 年 01 月 01 日至 2023 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-5 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | | 财务报表附注 | 1-123 | 审计报告 信会师报字[2024]第 ZD10061 号 我们审计了四川金石亚洲医药股份有限公司（以下简称金石亚药） 财务报表，包括 2023 年 12 月 31 日的合并及母公司资产负债表，2023 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公 司所有者权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的 规定编制，公允反映了金石亚药 2023 年 12 月 ...

Financial Performance - The company's revenue for Q1 2024 was ¥362,785,115.79, a decrease of 13.58% compared to ¥419,787,729.70 in the same period last year[4] - Net profit attributable to shareholders was ¥89,816,224.68, down 37.39% from ¥143,460,482.45 year-on-year[4] - Basic and diluted earnings per share decreased by 37.38% to ¥0.2236 from ¥0.3571 in the same quarter last year[4] - The net profit for Q1 2024 was CNY 89,543,650.31, a decrease of 37.1% compared to CNY 142,497,992.18 in Q1 2023[15] - Operating profit for Q1 2024 was CNY 115,048,924.11, down from CNY 184,249,348.46 in the same period last year, reflecting a decline of 37.6%[15] - Total revenue from sales in Q1 2024 was CNY 221,959,957.20, compared to CNY 350,792,078.64 in Q1 2023, indicating a decrease of 36.6%[17] - The total comprehensive income for Q1 2024 was CNY 89,543,650.31, compared to CNY 142,497,992.18 in Q1 2023, reflecting a decrease of 37.1%[16] Cash Flow and Assets - The net cash flow from operating activities was -¥90,480,979.33, representing a decline of 56.84% compared to -¥57,691,400.00 in the previous year[4] - Cash and cash equivalents decreased to CNY 444,143,577.19 from CNY 545,898,926.96, reflecting a decline of 18.5%[11] - The cash flow from operating activities for Q1 2024 was negative CNY 90,480,979.33, worsening from negative CNY 57,691,400.00 in Q1 2023[19] - The total current assets decreased to CNY 1,344,736,190.86 from CNY 1,371,587,670.56, a decline of 2.0%[12] - Total non-current assets increased to CNY 1,760,658,774.68 from CNY 1,729,850,994.45, an increase of 1.8%[12] Equity and Liabilities - Total assets at the end of the reporting period were ¥3,105,394,965.54, a slight increase of 0.13% from ¥3,101,438,665.01 at the end of the previous year[4] - Shareholders' equity attributable to the parent company increased by 3.74% to ¥2,490,245,750.15 from ¥2,400,429,525.47[4] - Total liabilities decreased to CNY 591,785,286.41 from CNY 677,372,636.19, a reduction of 12.6%[13] - The total equity attributable to shareholders increased to CNY 2,490,245,750.15 from CNY 2,400,429,525.47, an increase of 3.7%[13] Operating Costs and Expenses - The total operating costs for the current period amount to CNY 247,274,368.45, an increase of 4.4% from CNY 236,336,112.04 in the previous period[14] - Research and development expenses decreased to CNY 8,503,028.08 in Q1 2024 from CNY 17,587,226.51 in Q1 2023, a reduction of 51.6%[15] - The company incurred financial expenses of CNY -1,432,158.76 in Q1 2024, compared to CNY -627,377.47 in Q1 2023, indicating an increase in financial costs[15] Market and Operational Insights - The overall market demand for cold medicine products stabilized in Q1 2024, contributing to the decline in revenue and profit[7] - The company experienced a decrease in sales prepayments, impacting the net cash flow from operating activities[7] - The company reported non-recurring gains of ¥2,172,349.82 during the quarter, including government subsidies and other income[5] - The company reported a significant reduction in employee compensation payable, decreasing to CNY 33,896,086.08 from CNY 75,786,697.07, a decline of 55.3%[13] - Inventory decreased to CNY 225,394,191.50 from CNY 238,164,264.61, a decrease of 5.2%[12] - Accounts receivable increased to CNY 100,957,025.89 from CNY 79,477,350.02, representing a growth of 27.1%[11]

（汪立荔） 作为四川金石亚洲医药股份有限公司（以下简称"公司"）的独立董事，在 2023 年度工作中，本人严格按照《公司法》、《上市公司独立董事管理办法》、 《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管 指引第 2 号—创业板上市公司规范运作》以及《公司章程》、《公司独立董事工 作制度》等法律、法规、部门规章和规范性文件及公司规章制度的有关规定，独 立、勤勉地履行职责，有效发挥独立董事的作用，较好地维护了公司整体利益及 全体股东的合法权益。现将 2023 年度工作情况述职如下： 一、独立董事的基本情况 四川金石亚洲医药股份有限公司 2023 年度独立董事述职报告 (一)个人基本情况及工作履历 汪立荔，女，1977 年出生，本科学历，注册会计师。现任中审众环会计师 事务所（特殊普通合伙）上海自贸试验区分所合伙人，2017 年 10 月至 2023 年 12 月担任四川金石亚洲医药股份有限公司独立董事。 (二)关于独立性的情况说明 本人具备《上市公司独立董事管理办法》所要求的独立性，不存在影响独立 性的情况。 二、独立董事年度履职概况 (一)出席股东大会及董事会情况 2023 年度，公司 ...

四川金石亚洲医药股份有限公司 二、注册会计师的责任 内部控制鉴证报告 二○二三年度 内部控制鉴证报告 信会师报字[2024]第 ZD10062 号 四川金石亚洲医药股份有限公司全体股东： 我们接受委托，对四川金石亚洲医药股份有限公司（以下简称"金 石亚药"）董事会就 2023 年 12 月 31 日金石亚药财务报告内部控制 有效性作出的认定执行了鉴证。 一、董事会对内部控制的责任 金石亚药董事会的责任是按照《企业内部控制基本规范》的相关 规定建立健全和有效实施内部控制，评价其有效性，并如实披露内部 控制评价报告。 立信会计师事务所 中国注册会计师： 张 宇 我们的责任是在实施鉴证工作的基础上对财务报告内部控制的 有效性发表鉴证结论。 三、工作概述 我们按照《中国注册会计师其他鉴证业务准则第 3101 号——历 史财务信息审计或审阅以外的鉴证业务》的规定执行了鉴证业务。该 准则要求我们遵守中国注册会计师职业道德规范，计划和实施鉴证工 作，以对金石亚药是否于 2023 年 12 月 31 日在所有重大方面按照《企 业内部控制基本规范》的相关规定保持有效的财务报告内部控制获取 合理保证。在执行鉴证工作过程中，我们实 ...

非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 四川金石亚洲医药股份有限公司 2023 年度 | | | 占用方与上市公司 | 上市公司核算 | 2023 年期初 | 2023 年度占 用累计发生金 | 2023 年度占 | 2023 年度 | 2023 年期末 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | | 的会计科目 | 占用资金余 | | 用资金的利 | 偿还累计 | 占用资金余 | 原因 | 占用性质 | | | | 的关联关系 | | 额 | 额（不含利 | 息(如有) | 发生金额 | 额 | | | | | | | | | 息） | | | | | | | 控股股东、实际控制人及 | | | | | | | | | | | | 其附属企业 | | | | | | | | | | | | 小计 | - | - | - | | | | | | - | | | 前控股股东、实际控制人 | | | | | | | | | | | | 及 ...

证券代码：300434 证券简称：金石亚药 公告编号：2024-011 四川金石亚洲医药股份有限公司 关于召开 2023 年年度股东大会的通知 本公司及董事会全体成员保证公告内容的真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、 召开会议的基本情况 (一)会议的召开情况 （2）网络投票时间： 1、股东大会届次：2023 年年度股东大会 2、股东大会的召集人：公司第五届董事会 2024 年 4 月 24 日，公司第五届董事会第三次会议审议通过《关于召开 2023 年年度股东大会的议案》。 3、会议召开的合法、合规性：本次股东大会会议召开符合有关法律、行政 法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开的日期、时间 （1）现场会议召开时间：2024 年 5 月 24 日（星期五）下午 2：00 通过深圳证券交易所交易系统进行网络投票的时间为：2024 年 5 月 24 日的 交易时间，即 9:15—9:25，9:30—11:30 和 13:00—15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2024 年 5 月 24 日 09：15 至 15：00 的任意时间。 5 ...

证券代码：300434 证券简称：金石亚药 公告编号：2024-005 四川金石亚洲医药股份有限公司 关于 2023 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川金石亚洲医药股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日召开第五届董事会第三次会议、第五届监事会第三次会议审议通过了《2023 年度利润分配预案》，该议案尚需提交公司 2023 年年度股东大会审议。现将有关 情况公告如下： 一、2023 年度财务概况 经立信会计师事务所（特殊普通合伙）审计，公司 2023 年度实现归属于母 公司所有者的净利润 126,199,723.64 元，母公司 2023 年度实现净利润 -30,855,358.93 元。按照《公司法》、《公司章程》的规定，公司 2023 年不提取法 定盈余公积。截止 2023 年 12 月 31 日，经审计合并可供股东分配的利润为 147,408,521.58 元，母公司口径可供股东分配的利润为 388,048,421.68 元。根据 《深圳证券交易所上市公司自律监管指引第 2 号—创业板上 ...

一、独立董事的基本情况 （一）个人基本情况及工作履历 四川金石亚洲医药股份有限公司 2023 年度独立董事述职报告 （马文杰） 作为四川金石亚洲医药股份有限公司（以下简称"公司"）的独立董事，在 2023 年度工作中，本人严格按照《公司法》、《上市公司独立董事管理办法》、 《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管 指引第 2 号—创业板上市公司规范运作》以及《公司章程》、《公司独立董事工 作制度》等法律、法规、部门规章和规范性文件及公司规章制度的有关规定，独 立、勤勉地履行职责，有效发挥独立董事的作用，较好地维护了公司整体利益及 全体股东的合法权益。现将 2023 年度工作情况述职如下： 马文杰，男，1982 年出生，法律硕士，2016 年 3 月至今任上海文飞永律师 事务所主任，现任鸿利智汇独立董事，2017 年 10 月至 2023 年 12 月担任四川金 石亚洲医药股份有限公司独立董事。 （二）关于独立性的情况说明 本人具备《上市公司独立董事管理办法》所要求的独立性，不存在影响独立 性的情况。 二、独立董事年度履职概况 （一）出席股东大会及董事会情况 2023 年度，公司共 ...

2023 年度监事会工作报告 2023 年，四川金石亚洲医药股份有限公司（以下简称"公司"）监事会，从 切实维护公司利益和广大股东权益出发，严格依照《公司法》、《证券法》等法律 法规，以及《公司章程》、《监事会议事规则》的有关规定，认真履行和独立行使 监事会的监督职权和职责。公司监事通过参加监事会会议、列席董事会会议、与 公司董事及高级管理人员沟通交流、检查公司各项工作报告和财务报告等形式， 对公司的生产经营、重大事项、财务状况、内部控制、信息披露、关联交易以及 董事、高级管理人员履行职责等方面进行了有效的审查和监督，较好地保障了公 司股东权益、公司利益和员工的合法权益，促进了公司的规范化运作。现将 2023 年度监事会主要工作汇报如下： 四川金石亚洲医药股份有限公司 报告期内，在公司全体股东的大力支持下，在董事会和管理层的积极配合下， 监事列席了董事会和股东大会会议，参与公司重大决策的讨论，依法监督各次董 事会和股东大会的议案和会议召开程序。 一、2023 年度监事会工作情况 报告期内，公司共召开监事会会议 6 次，全体监事均亲自出席会议，不存在 缺席会议的情况。监事会会议的召集、召开程序符合《公司法》、《 ...